明显
发表于 2025-3-21 16:41:49
书目名称Cardio-Oncology影响因子(影响力)<br> http://impactfactor.cn/if/?ISSN=BK0221854<br><br> <br><br>书目名称Cardio-Oncology影响因子(影响力)学科排名<br> http://impactfactor.cn/ifr/?ISSN=BK0221854<br><br> <br><br>书目名称Cardio-Oncology网络公开度<br> http://impactfactor.cn/at/?ISSN=BK0221854<br><br> <br><br>书目名称Cardio-Oncology网络公开度学科排名<br> http://impactfactor.cn/atr/?ISSN=BK0221854<br><br> <br><br>书目名称Cardio-Oncology被引频次<br> http://impactfactor.cn/tc/?ISSN=BK0221854<br><br> <br><br>书目名称Cardio-Oncology被引频次学科排名<br> http://impactfactor.cn/tcr/?ISSN=BK0221854<br><br> <br><br>书目名称Cardio-Oncology年度引用<br> http://impactfactor.cn/ii/?ISSN=BK0221854<br><br> <br><br>书目名称Cardio-Oncology年度引用学科排名<br> http://impactfactor.cn/iir/?ISSN=BK0221854<br><br> <br><br>书目名称Cardio-Oncology读者反馈<br> http://impactfactor.cn/5y/?ISSN=BK0221854<br><br> <br><br>书目名称Cardio-Oncology读者反馈学科排名<br> http://impactfactor.cn/5yr/?ISSN=BK0221854<br><br> <br><br>
chuckle
发表于 2025-3-21 22:05:26
http://reply.papertrans.cn/23/2219/221854/221854_2.png
Collar
发表于 2025-3-22 02:20:21
http://reply.papertrans.cn/23/2219/221854/221854_3.png
阴险
发表于 2025-3-22 07:29:30
Management of Patients with Cardiac Toxicity: The Point of View of the Oncologist,iological toxicities. Different types of cardiotoxicity can also occur with cell-based immune-therapy treatments (e.g., CAR-T), requiring specific diagnosis and management protocols. Because of the high morbidity and mortality, an early diagnosis of cardiological irAEs is essential for framing the o
phlegm
发表于 2025-3-22 12:44:09
http://reply.papertrans.cn/23/2219/221854/221854_5.png
CHIDE
发表于 2025-3-22 16:27:13
http://reply.papertrans.cn/23/2219/221854/221854_6.png
CHIDE
发表于 2025-3-22 18:36:25
http://reply.papertrans.cn/23/2219/221854/221854_7.png
Outshine
发表于 2025-3-22 23:07:32
http://reply.papertrans.cn/23/2219/221854/221854_8.png
祖传
发表于 2025-3-23 05:06:39
Atemwegssicherung, Intubation und Beatmung,ligand-1 (PD-L1) checkpoint inhibitors have a crucial role in oncological treatments, resulting in an improvement of progression-free survival (PFS) and overall survival (OS) compared with standard treatments. Moreover, different safety analyses established that immunotherapy is well-tolerated with
结构
发表于 2025-3-23 06:12:27
,Störungen der Vitalfunktionen,scular system. The most clinically relevant cardiovascular adverse event is myocarditis, with an incidence rate ranging from 0.27% of patients treated with single-agent ICIs up to 2.4% of patients treated with combinations. Immune-related myocarditis is burdened by high mortality, with a fatality ra